Genetic Basis of Familial Hypertriglyceridemia
Familial hypertriglyceridemia (FHTG) is a common polygenic disorder affecting 5-10% of the population, characterized by VLDL overproduction and reduced VLDL catabolism resulting in saturation of lipoprotein lipase (LPL), with triglyceride levels typically ranging from 200-1000 mg/dL. 1
Inheritance Pattern and Genetic Architecture
FHTG follows a polygenic inheritance pattern rather than simple Mendelian genetics 2. This distinguishes it fundamentally from rare monogenic causes of severe hypertriglyceridemia:
- Not caused by single gene mutations like LPL deficiency, ApoC-II deficiency, or ApoA5 homozygosity
- Results from the cumulative effect of multiple common genetic variants (single nucleotide polymorphisms) with small individual effects 3, 4
- Environmental factors (obesity, stress, diet) are required for clinical expression, which is why it typically manifests in adulthood 1
Key Distinguishing Features from Monogenic Disorders
The genetic profile of FHTG differs markedly from severe monogenic hypertriglyceridemia:
FHTG characteristics:
- Polygenic risk score accounts for approximately 6.73% of triglyceride variance 5
- ApoB levels remain normal (unlike familial combined hyperlipidemia) 1
- Requires secondary triggers to reach severe levels (>1000 mg/dL) 1
- More than 300 genetic loci have been identified in genome-wide association studies 3
Monogenic severe hypertriglyceridemia (for comparison):
- Autosomal recessive inheritance with biallelic mutations in LPL, APOC2, APOA5, LMF1, or GPIHBP1 1
- Triglycerides typically >1000 mg/dL even without secondary factors
- Accounts for only 1.1% of severe hypertriglyceridemia cases 6
Pathophysiology
The genetic variants in FHTG lead to:
- Increased hepatic VLDL triglyceride synthesis - producing very large, triglyceride-enriched VLDL particles
- Reduced VLDL catabolism - leading to saturation of LPL capacity 1, 2
- Normal particle number - distinguishing it from familial combined hyperlipidemia where apoB-containing particles are overproduced 2
Clinical Implications of the Polygenic Nature
Critical point: Recent evidence demonstrates that up to 46.3% of patients with severe hypertriglyceridemia have polygenic rather than monogenic disease 6. This has major implications:
- Cardiovascular risk is generally low unless metabolic syndrome features coexist or baseline triglycerides are high (≥200 mg/dL) 1
- Pancreatitis risk increases when secondary factors (alcohol, uncontrolled diabetes, certain medications) push triglycerides above 1000 mg/dL 1
- Treatment response differs from monogenic forms - FHTG typically responds better to lifestyle modification and standard pharmacotherapy 5
Genetic Testing Considerations
While genetic testing can identify polygenic risk:
- Polygenic risk scores can discriminate FHTG from normolipidemia, particularly at extreme scores 4
- However, 52.6% of severe hypertriglyceridemia remains genetically undefined even with comprehensive sequencing 6
- Testing for rare monogenic variants is most useful when triglycerides are persistently >1000 mg/dL despite treatment, or when pancreatitis occurs 7
Distinguishing FHTG from Other Genetic Dyslipidemias
Familial Combined Hyperlipidemia (FCHL): Genetically complex with elevated apoB levels (>90th percentile), multiple affected relatives with varying lipid abnormalities 1
Dysbetalipoproteinemia: Requires apoE2/E2 genotype plus a second genetic or acquired defect; both cholesterol and triglycerides elevated equally 1
Heterozygous LPL or ApoA5 deficiency: Rare variants requiring secondary triggers to manifest; 14.4% of severe hypertriglyceridemia 6
The polygenic nature of FHTG means that no single genetic test will identify the cause, and diagnosis remains primarily clinical based on triglyceride levels, family history, and exclusion of secondary causes and monogenic disorders 7, 2.